Connection

Paolo Gisondi to Female

Back to Details
This is a "connection" page, showing publications Paolo Gisondi has written about Female.
Paolo Gisondi
Connection Strength
0.135
Female
  1. The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. Clin Exp Rheumatol. 2021 Sep-Oct; 39(5):1099-1107.
    View in: PubMed
    Score: 0.012
  2. Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience. J Allergy Clin Immunol. 2021 Feb; 147(2):558-560.e1.
    View in: PubMed
    Score: 0.012
  3. Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. J Eur Acad Dermatol Venereol. 2020 Jun; 34(6):1196-1201.
    View in: PubMed
    Score: 0.012
  4. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol. 2020 08; 183(2):373-374.
    View in: PubMed
    Score: 0.012
  5. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment. J Am Acad Dermatol. 2020 Jul; 83(1):285-287.
    View in: PubMed
    Score: 0.012
  6. Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. Br J Dermatol. 2017 12; 177(6):e325-e326.
    View in: PubMed
    Score: 0.010
  7. Severe cutaneous aluminum reaction to quadrivalent human papillomavirus vaccine treated with cyclosporin. J Dermatol. 2017 Dec; 44(12):e332-e333.
    View in: PubMed
    Score: 0.010
  8. Public perception of dermatology and dermatologists in Italy: results from a population-based national survey. J Eur Acad Dermatol Venereol. 2017 Dec; 31(12):2119-2123.
    View in: PubMed
    Score: 0.010
  9. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol. 2013 May; 168(5):1124-7.
    View in: PubMed
    Score: 0.007
  10. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. Expert Opin Biol Ther. 2021 02; 21(2):271-277.
    View in: PubMed
    Score: 0.003
  11. Hidradenitis suppurativa and adalimumab in the COVID-19 era. Eur J Dermatol. 2020 Dec 01; 30(6):748-749.
    View in: PubMed
    Score: 0.003
  12. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2021 01; 147(1):60-71.
    View in: PubMed
    Score: 0.003
  13. Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy. Am J Clin Dermatol. 2020 10; 21(5):749-751.
    View in: PubMed
    Score: 0.003
  14. Psoriasis is not associated with cognition, brain imaging markers, and risk for dementia: The Rotterdam Study. J Am Acad Dermatol. 2021 09; 85(3):671-680.
    View in: PubMed
    Score: 0.003
  15. Ultrasonography of the nail unit reveals quantitative and qualitative alterations in patients with psoriasis and psoriatic arthritis. Med Ultrason. 2018 May 02; 20(2):177-184.
    View in: PubMed
    Score: 0.003
  16. Kyrle's disease effectively treated with oral isotretinoin. J Dermatolog Treat. 2018 Sep; 29(6):630-632.
    View in: PubMed
    Score: 0.002
  17. Effects of secukinumab on serum adipocytokines: preliminary data. Reumatismo. 2017 Sep 21; 69(3):105-110.
    View in: PubMed
    Score: 0.002
  18. Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. J Dermatolog Treat. 2018 May; 29(3):217-219.
    View in: PubMed
    Score: 0.002
  19. Primary Cutaneous CD4+ Small/Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series. J Cutan Med Surg. 2017 Nov/Dec; 21(6):502-506.
    View in: PubMed
    Score: 0.002
  20. A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). Br J Dermatol. 2017 Jul; 177(1):197-205.
    View in: PubMed
    Score: 0.002
  21. Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. Dermatol Ther. 2017 Sep; 30(5).
    View in: PubMed
    Score: 0.002
  22. Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. Ann Rheum Dis. 2017 Sep; 76(9):1591-1597.
    View in: PubMed
    Score: 0.002
  23. Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. J Eur Acad Dermatol Venereol. 2017 May; 31(5):863-869.
    View in: PubMed
    Score: 0.002
  24. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol. 2017 Nov; 31(11):1853-1859.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.